Farmington, United States
RIGImmune Inc. is a promising player in the biopharmaceutical industry, with a sharp focus on pioneering RNA therapeutics to tackle serious respiratory diseases. Founded in 2020, this innovative company thrives on the cutting-edge discoveries of co-founders Drs. Akiko Iwasaki and Anna Pyle from Yale University.
With its slogan, "Targeted non-LNP Delivery of RNA Therapeutics," RIGImmune has taken a distinctive approach by developing stem-loop RNA therapeutics (SLRs) and leveraging a proprietary delivery platform called NEED™. In collaboration with SubIntro, and supported by seasoned developers like Drs. Garth Rapeport, Kazuhiro Ito, and Jag Shur, the company aims to enhance the innate immune response against viral respiratory diseases and address conditions like cystic fibrosis.
Headquartered in the United States and active within the biopharma, biotechnology, and pharmaceutical sectors, RIGImmune is yet to make its mark with a significant investment round. This growing entity presents a compelling opportunity for investors interested in transformative medical innovations.
